About ImaginAb
ImaginAb is a company based in Los Angeles (United States) founded in 2007. It operates as a HealthTech. ImaginAb has raised $59.64 million across 6 funding rounds from investors including Novartis, Theravance Biopharma and HHS. ImaginAb offers products and services including CD8 ImmunoPET and PSMA Optical Imaging. ImaginAb operates in a competitive market with competitors including Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
- Headquarter Los Angeles, United States
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
- Legal Name Imaginab, Inc.
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$59.64 M (USD)
in 6 rounds
-
Latest Funding Round
$12.8 M (USD), Series C
Jun 03, 2021
-
Investors
Novartis
& 12 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of ImaginAb
ImaginAb offers a comprehensive portfolio of products and services, including CD8 ImmunoPET and PSMA Optical Imaging.
Advanced imaging agent for visualizing CD8 cell activity.
Optical imaging solution for prostate and renal cancer.
People of ImaginAb
Unlock access to complete
Unlock access to complete
Funding Insights of ImaginAb
ImaginAb has successfully raised a total of $59.64M across 6 strategic funding rounds. The most recent funding activity was a Series C round of $12.8 million completed in June 2021. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in ImaginAb
ImaginAb has secured backing from 13 investors, including venture fund, institutional, and angel investors. Prominent investors backing the company include Novartis, Theravance Biopharma and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Investment and strategic support are provided by Raptor Group.
|
Locked | Locked | Locked | |
|
-
|
Locked | Locked | Locked | |
|
Stage agnostic VC firm investing primarily in the US
|
Locked | Locked | Locked |
Investor details for ImaginAb
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by ImaginAb
Investment portfolio details for ImaginAb
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - ImaginAb
Detailed financials for ImaginAb
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Imaginab Comparisons
Peer comparison for ImaginAb
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of ImaginAb
ImaginAb operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Guardant Health, Foundation Medicine, ArcherDX, Natera and Strand Life Sciences, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Digital sequencing technology for cancer detection is developed.
|
|
| Locked | Locked | Locked |
Genomics-based diagnostic tests for cancer are provided.
|
|
| Locked | Locked | Locked |
Molecular cancer diagnostic products are developed using patented AMP technology.
|
|
| Locked | Locked | Locked |
Developer of cell-free DNA testing for oncology, women’s health, and organ health
|
|
| Locked | Locked | Locked |
Provider of omics-based solutions for clinical genomics, systems biology, and drug discovery
|
|
| Locked | Locked | Locked |
Health risks are identified through online genetic and diagnostic testing.
|
Detailed competitors of ImaginAb
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Imaginab
Complete news archive for ImaginAb
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about ImaginAb
ImaginAb was founded in 2007 and raised its 1st funding round 4 years after it was founded.
ImaginAb is headquartered in Los Angeles, United States. It is registered at Los Angeles, California, United States.
ImaginAb is a funded company, having raised a total of $59.64M across 6 funding rounds to date.
ImaginAb is engaged in the development of cutting-edge radiopharmaceutical imaging technologies, primarily through its CD8 ImmunoPET agent, which is designed to provide detailed visual profiles of immunity status in patients. The company operates in the healthcare and biotechnology sectors, targeting immuno-oncology and autoimmune diseases. Solutions are offered to enhance patient care paths by enabling physicians to visualize treatment impacts before, during, and after therapy. Additionally, pipeline innovations include optical imaging for prostate and renal cancer, aiming to transform diagnostic and therapeutic approaches in oncology.
ImaginAb's top competitors include Guardant Health, Strand Life Sciences and Foundation Medicine.
ImaginAb offers CD8 ImmunoPET and PSMA Optical Imaging.
ImaginAb has 13 investors. Key investors include Novartis, Theravance Biopharma, HHS, Momentum Bioscience, and Raptor Group.